scholarly journals Small cell carcinoma as an independent prognostic factor for cervical cancer patients: a population-based analysis

2021 ◽  
Author(s):  
Wang Miao ◽  
Wu Qiuji ◽  
Song Congkuan ◽  
Liu Yixin ◽  
Wang Xulong ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Small Cell Carcinoma ◽  
Cox Regression ◽  
Small Cell ◽  
Poor Prognostic Factor ◽  
Gynecology And Obstetrics ◽  
Before And After

Aim: To compare cervical small cell carcinoma (SmCC) with squamous cell carcinoma (SCC) in patient characteristics and survival outcomes. Methods: Cervical SmCC and SCC patients in Surveillance, Epidemiology, and End Results database from 2004 to 2015 were enrolled. Propensity-score matching analysis (PSM) paired subjects with similar background variables. Cox regression, Kaplan–Meier and stratified analyses were conducted before and after PSM. Results: Cervical SmCC patients showed a higher rate of larger tumor size, advanced grade disease, lymph node involvement and distant metastasis (p < 0.001). Before and after PSM, SmCC histology and advanced Federation International of Gynecology and Obstetrics stages (p < 0.001) were principal prognostic factors of survival, and cervical SmCC was associated with worse survival in all stages (stage I–IV). Conclusion: SmCC was an independent poor prognostic factor in cervical cancer patients.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

Lung Cancer ◽  
2015 ◽  
Vol 89 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Wendy A. Cooper ◽  
Thang Tran ◽  
Ricardo E. Vilain ◽  
Jason Madore ◽  
Christina I. Selinger ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Early Stage ◽  
Small Cell ◽  
Favorable Prognostic Factor

Differential expressions of PD-1, PD-L1, and PD-L2 between the primary and metastatic sites in renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 616-616
Author(s):  
Xingming Zhang ◽  
Pengfei Shen ◽  
Hao Zeng
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cox Regression ◽  
Predictive Accuracy ◽  
Biological Information ◽  
Poor Prognostic Factor ◽  
Cox Regression Analysis ◽  
Metastatic Sites

616 Background: To evaluate the differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastatic sites of renal cell carcinoma (RCC), and to find potential factors influencing expression difference. Methods: We included cases of RCC histologically diagnosed at West China Hospital between January 2009 and November 2016. Clinicopathological data were retrospectively extracted. SPPS 22.0 and GraphPad Prism 6 statistical software were used for data analysis. Kaplan-Meier was used to analyze PFS and OS. R software was used to calculate predictive accuracy (PA). Results: A total of 163 patients were included in this study. Immunohistochemistry results suggested significant differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastasis, with a higher detection rate of the primary than metastasis. Meanwhile, the concordance rate of PD-L1 between the primary and metastasis was only 32.5% (27/83), with a significant statistically difference (χ2 = 4.664, p = 0.031) and poor consistency (Kappa = 0.229, p = 0.031). PD-1 and PD-L1 were highly expressed in the lung/lymph node and PD-L2 was highly expressed in visceral metastases. Survival analysis suggested that PD-1 positive either in the primary or metastasis was a poor prognostic factor for OS (HR: 1.59, 95% CI 1.08-2.36, P = 0.0195). The expression of PD-L1 in the primary was a poor prognostic factor for OS (HR 2.55, 95% CI 1.06-6.15, P = 0.0373). Although the predictive effect of PD-L1 expression on OS was not statistically significant in TKI treated patients, the OS time was shorter in PD-L1-positive patients than those negative (median OS 19.0 vs 41.0 months). In the whole cohort, the PA value of COX regression analysis was 0.683 for PFS, and the addition of PD-1 expression in the primary increased the PA value to 0.699. Conclusions: The assessment of immunological checkpoint-related protein in primary tumor may not be able to provide adequate information for clinicians to evaluate or predict the patient's treatment-related efficacy and prognosis. Biopsy or resection of the metastases may provide a more accurate biological information for clinician's decision-making and the patient's prognosis.

Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 425-425 ◽  
Author(s):  
Jeanny B. Aragon-Ching ◽  
Donald Henson
Keyword(s):  
Squamous Cell Carcinoma ◽  
Survival Rate ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Median Survival ◽  
Squamous Cell ◽  
Cox Regression ◽  
Small Cell ◽  
Urothelial Bladder ◽  
Incident Cases

425 Background: Non-urothelial cancers of the urinary bladder are rare, and typically < 5% incidence. They are generally considered more aggressive without clear guidelines for treatment. Methods: Incident cases of non-urothelial bladder cancers that included squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcomas were identified in the SEER (Surveillance, Epidemiology, and End Results) Database. Demographic information, pathologic characteristics and 5-year disease-specific survival were calculated and compared using multivariate Cox regression and Kaplan-Meier curves. Results: A total of 235,537 incident cases of bladder carcinomas were identified in the years 1998 – 2008, of which 3096 cases were squamous cell carcinoma, 1175 were neuroendocrine carcinoma where small cell carcinomas made up the majority with 859 patients, 671 was comprised of adenocarcinomas, representing 0.28%, and sarcomas were 88 cases, making up 0.03% of all cases combined. The majority of patients were White (90%) although more African-Americans (15%) were seen with adenocarcinoma. The table shows the number of cases and 5-year survival according to stage. Median survival was greatest for adenocarcinoma at 179 months with a 5–year survival rate of 58%, followed by sarcomas with a median survival of 23 months, with a 5-year survival rate of 47%, followed by squamous cell carcinomas with a median survival time of 15 months and a 5-yr survival rate of 37% and the least favorable survival was for small cell carcinoma, 17 months median time, with a 5-yr survival rate of 31%. Conclusions: Non-urothelial cancers have a uniformly less favorable survival compared to urothelial cancers, highlighting the need for improved therapeutic strategies in these cohorts of patients. [Table: see text]

scholarly journals Hypercalcemic type of small cell carcinoma of the ovary

2015 ◽  
Vol 72 (3) ◽  
pp. 295-298 ◽  
Author(s):  
Milena Ilic ◽  
Dalibor Jovanovic ◽  
Milos Milosavljevic ◽  
Vesna Stankovic ◽  
Gordana Djordjevic ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Good Condition ◽  
Fatal Outcome ◽  
Regular Structure ◽  
Small Cell ◽  
Lower Abdomen ◽  
Gynecology And Obstetrics ◽  
Extrapulmonary Small Cell Carcinoma ◽  
Carcinoma Of The Ovary

Introduction. Extrapulmonary small cell carcinoma is a rare, prognostically bad tumor category. Primary, it can be localized in every organ, even in the ovary, where, due to its clinical specificities, it represents a challenge in diagnosis, as well as in therapy. Small cell ovarian carcinoma (SCOC) is biologically very aggressive malignant tumor of unknown histogenesis. We presented a rare case of SCOC with hypercalcemia of aggressive course and fatal outcome in a postmenopausal woman at International Federation of Gynecology and Obstetrics (FIGO) Ia stage. Case report. A 60-year-old woman, Caucasian, came to the doctor because of discomfort in the lower abdomen and pain of greater intensity in last few days. Ultrasound examination and CT scan of the abdomen confirmed the presence of large adnexal masses of cystic-solid appearance with the largest diameter of 13 cm, regular structure of the other gynecological organs, without verifying the existence of metastatic deposits. All the results of laboratory analysis gave normal values, except for calcium, which was elevated. Explorative laparotomy with complete hysterectomy, bilateral salpingo-oophorectomy, dissection of lymph nodes and omentectomy were conducted. Based on pathohistological analysis of the operative material, SCOC at FIGO Ia stage was diagnosed. No complications were observed in a postsurgery period and after 10 days the patient was discharged in a good condition and with normal calcemia. The treatment was continued with concurrent radiotherapy and chemotherapy. However, in spite of overall treatment, the disease progressed, and the patient died of disseminated metastatic disease, 26 months after the diagnosis. Conclusion. Small cell carcinoma localized in the ovary is generally a tumor category with bad prognosis depending on the stage of the disease.

Sign in / Sign up

Export Citation Format

Share Document